AstraZeneca Seeks To Block Dr Reddy’s US Brilinta Rival
Executive Summary
AstraZeneca has petitioned a US court to stop India’s Dr Reddy’s from launching a generic version of its blood clot-fighting drug Brilinta, accusing the Indian drugmaker of patent infringement.